|
| Press Releases |
|
 |
|
| Thursday, May 2, 2024 |
|
|
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore |
| Mainboard listed Q&M Dental Group (Singapore) Limited ("Q&M" or "the Company" and together with its subsidiaries, the "Group") is proud to announce its integration of Align Technology's ("Align") iTero Lumina(TM) Intraoral Scanner in Singapore. more info >> |
|
| Tuesday, April 23, 2024 |
|
|
EM2AI Revolutionising the Dental Industry: New AI Products Promise Transparent Treatment Plans for Patients |
| EM2AI Pte. Ltd., ("EM2AI" or the "Company") an Artificial Intelligence (AI) dental healthcare company based in Singapore today announced a groundbreaking development poised to reshape the landscape of dental care, with the launch of its pioneering dental AI product. more info >> |
|
| Friday, March 3, 2023 |
|
|
CATALIST-listed AOXIN Q&M reports lower revenue of RMB 140m for full year ended 31 December 2022 |
| Catalist listed Aoxin Q&M Dental Limited, announced on 1 March 2023, a 12.8% lower revenue of RMB139.7 million for full year ended 31 December 2022 (FY2022). The Group reported a net loss after tax excluding impairment loss on investment in our associate of RMB7.3 million for FY2022, primarily due to the number of shutdowns from China's zero-Covid policy that was in place all the way up until 8 January 2023. more info >> |
|
| Wednesday, February 23, 2022 |
|
|
CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021 |
| Catalist listed Aoxin Q&M Dental Limited ("Aoxin" or "the Group"), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 ("FY2021"). more info >> |
|
| Monday, October 4, 2021 |
|
|
Aoxin Q & M acquires 49% stake in Acumen Diagnostics for S$29.4m |
| Aoxin Q & M Dental Group Ltd (SGX: 1D4.SI) ("Aoxin Q & M") and Q & M Dental Group (Singapore) Limited (SGX: QC7.SI) ("Q & M"), announced today that Aoxin Q & M will acquire 49% of Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") for a consideration of S$29.4 million. Acumen Diagnostics has a preliminary valuation of S$60 million. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
AdsDrama Launches Short-Drama Marketing Ecosystem Launch in the Dominican Republic, Paving the Way for Digital Content Innovation
Mar 14, 2026 05:00 HKT/SGT
|
|
|
General MRO Aerospace 取得中國民航局認證，拓展全球維修能力
Mar 13, 2026 22:20 HKT/SGT
|
|
|
General MRO Aerospace 获得中国民航局认证，拓展全球维护能力
Mar 13, 2026 22:20 HKT/SGT
|
|
|
General MRO Aerospace Achieves CAAC Certification, Expanding Global Maintenance Capabilities
Mar 13, 2026 22:20 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
Mar 13, 2026 22:00: JST
|
|
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
Mar 13, 2026 22:00 HKT/SGT
|
|
|
CITIC Resources Deepens Dual-Engine Strategy of 'Investment + Trading', Continues to Promote High-Quality Development
Mar 13, 2026 21:01 HKT/SGT
|
|
|
中信資源深化「投資+貿易」雙輪戰略 持續驅動高質量發展 推進「上游資產布局、貿易業務拓展、生產運營提質」
Mar 13, 2026 20:53 HKT/SGT
|
|
|
中信资源深化「投资+贸易」双轮战略 持续驱动高质量发展 推进「上游资产布局、贸易业务拓展、生产运营提质」
Mar 13, 2026 20:40 HKT/SGT
|
|
|
康哲藥業：腎性貧血新藥德昔度司他片中國獲批上市
Mar 13, 2026 20:24 HKT/SGT
|
|
|
康哲药业：肾性贫血新药德昔度司他片中国获批上市
Mar 13, 2026 20:15 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
Mar 13, 2026 18:00: JST
|
|
|
uSMART HK Expands to 12 Physical Service Centres in One Year, Accelerating "Online x Offline" O2O Community Finance Strategy
Mar 13, 2026 17:34 HKT/SGT
|
|
|
盈立證券一年拓展12個服務網點 全力深化「線上x線下」O2O社區金融佈局
Mar 13, 2026 17:21 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
Mar 13, 2026 17:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
